- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00831987
Safety and Immunogenicity of the World Health Organization (WHO) Formulation of the 2004-2005 Fluzone® Vaccine
Annual Study of Safety and Immunogenicity of Influenza Virus Vaccine Fluzone® 2004-2005
To observe and to describe the safety during Days 0 to 21 following injection of the 2004-2005 formulation of the inactivated, split-virion influenza vaccine Fluzone® in subjects aged 18-59 years and subjects aged ≥ 60 years.
To measure and to describe the immune response (antibodies to hemagglutinin) 21 days following injection of the 2004-2005 formulation of the inactivated, split-virion influenza vaccine Fluzone®, in subjects aged 18-59 years and subjects aged ≥ 60 years.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
The time of onset and duration of local and systemic solicited reactions will be assessed and reported. Unsolicited adverse events (including serious adverse events) will be collected and categorized throughout the study period.
Antibody levels will be evaluated by hemagglutination inhibition (HI) assay from sera obtained pre-vaccination (Day 0) and 21 days post-vaccination, for antigens from the 2004-2005 influenza virus strains: A/New Caledonia/20/99 (H1N1), A/Wyoming/03/2003 (H3N2), and B/Jiangsu/10/2003.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 4
Contacten en locaties
Studie Locaties
-
-
Virginia
-
Norfolk, Virginia, Verenigde Staten, 23507
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria :
- Participant aged 18 years or older.
- Participant able to attend scheduled visits and to comply with the study procedures during the entire duration of the study.
- Participant is in reasonably good health as assessed by the investigator.
- Participant willing and able to meet protocol requirements.
- Participant willing and able to give informed consent.
Exclusion Criteria :
- Self-reported allergy to egg proteins, chicken proteins, or one of the constituents of the vaccine, such as thimerosal or formaldehyde.
- An acute illness with or without fever (temperature >100.4°F) in the 72 hours preceding enrollment in the trial.
- Clinically significant findings in vital signs (including temperature >100.4°F) on review of systems.
- Self-reported history of severe adverse event to any influenza vaccine.
- Vaccination against influenza in the 6 months preceding enrollment in the study.
- Any vaccination in the 14 days preceding enrollment in the study or scheduled between Visit 1 and Visit 3.
- Participation in any other experimental drug or vaccine trial within the 30 days preceding enrollment into the study.
- Immunogenicity or immunosuppressive therapy (including systemic steroid use for 2 weeks or more), cancer chemotherapy, or radiation therapy at the time of enrollment, planned during the period of this study, or at any time within the past 3 months.
- Receipt of blood or blood products within the 3 months preceding enrollment in the study.
- Diabetes mellitus requiring pharmacological control.
- Any condition that in the opinion of the investigator would pose a health risk to the subject if enrolled, or could interfere with the evaluation of the vaccine.
- Person deprived of freedom by an administrative or court order (having legal or medical guardian).
- For women of childbearing age, a positive urine pregnancy test, breast feeding, or not using a medically approved and reliable form of contraception (oral contraceptives or double barrier method) for the duration of the trial.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Preventie
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Fluzone® Vaccine Group - Age 18-59 Years
Participants aged 18 to 59 years at enrollment and received 1 dose of Fluzone® Vaccine
|
0.5 mL, Intramuscular
Andere namen:
|
Experimenteel: Fluzone® Vaccine Group - Age ≥ 60 Years
Participants aged at least 60 years or older at enrollment and received 1 dose of Fluzone® Vaccine
|
0.5 mL, Intramuscular
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Percentage of Participants With Solicited Local and Systemic Reactions After Fluzone® Vaccination
Tijdsspanne: 0 to 3 days post-vaccination
|
Solicited local reactions: Erythema (redness), Induration, Bruising, and Pain at the injection site. Solicited systemic events: Fever (temperature), Chills, Rash, Headache, Cough, Runny nose, Nausea, Vomiting, Diarrhea, Malaise, Myalgia, and Arthralgia |
0 to 3 days post-vaccination
|
Geometric Mean Titers (GMTs) of Hemagglutination Antibodies Pre- and Post-Vaccination With Fluzone® Vaccine
Tijdsspanne: Day 0 and Day 21 Post-Vaccination
|
GMTs and their 95% Confidence Intervals for each of the 3 antigens pre- and post-vaccination with Fluzone® 2004-2005 formulation.
|
Day 0 and Day 21 Post-Vaccination
|
Percentage of Participants With at Least 40 Serum Hemagglutination Inhibition Antibody Titers Post-Vaccination
Tijdsspanne: 21 Days post-vaccination
|
21 Days post-vaccination
|
|
Percentage of Participants With at Least a 4-Fold Increase in Serum Hemagglutination Inhibition Antibody Titers Post-Vaccination
Tijdsspanne: Day 21 post-vaccination
|
Day 21 post-vaccination
|
Medewerkers en onderzoekers
Sponsor
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- GRC20
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Influenza
-
Gamaleya Research Institute of Epidemiology and...VoltooidGriep A | Influenza A-virusinfectie | Influenza-epidemie | Influenza H5N1Russische Federatie
-
Vanderbilt University Medical CenterHuman Vaccines ProjectVoltooidVaccin reactie | Influenza | Influenza, mens | Griep A | Influenza type B | Influenza A H3N2 | Influenza A H1N1Verenigde Staten
-
NPO PetrovaxVoltooidVaccin reactie | Influenza | Influenza, mens | Griep A | Acute luchtweginfectie | Influenza type B | Griep | Influenza A H3N2 | Influenza A H1N1 | Griep, mens | Influenza-epidemieRussische Federatie
-
Quidel CorporationVoltooidInfluenza A, Influenza BVerenigde Staten
-
Vaxine Pty LtdAustralian Respiratory and Sleep Medicine InstituteVoltooid
-
Ology BioservicesVoltooidInfluenza, vogelAustralië, Finland, Singapore, Spanje
-
Henry M. Jackson Foundation for the Advancement...National Institute of Allergy and Infectious Diseases (NIAID); Food and Drug... en andere medewerkersActief, niet wervendInfluenza | Influenza-achtige ziekte | Influenza vaccinsVerenigde Staten
-
AVIR Green Hills Biotechnology AGVoltooidInfluenza, vogelRussische Federatie
-
National Institute of Allergy and Infectious Diseases...Voltooid
-
National Institute of Allergy and Infectious Diseases...Voltooid
Klinische onderzoeken op Fluzone®: Influenza virus vaccine 2004-2005 formulation
-
Sanofi Pasteur, a Sanofi CompanyVoltooid
-
Sanofi Pasteur, a Sanofi CompanyVoltooidInfluenzaVerenigde Staten
-
National Institute of Allergy and Infectious Diseases...Atopic Dermatitis Research NetworkVoltooidDermatitis, atopischVerenigde Staten
-
Sanofi Pasteur, a Sanofi CompanyVoltooidInfluenza | Orthomyxoviridae-infectie | Myxovirus-infectieVerenigde Staten, Puerto Rico
-
Sanofi Pasteur, a Sanofi CompanyVoltooid
-
Sanofi Pasteur, a Sanofi CompanyVoltooidInfluenzaVerenigde Staten
-
Sanofi Pasteur, a Sanofi CompanyVoltooid
-
Sanofi Pasteur, a Sanofi CompanyVoltooidInfluenzaVerenigde Staten, Puerto Rico
-
Protein Sciences CorporationVoltooid